NCT04786028View on ClinicalTrials.gov

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2027

Conditions
Multiple Myeloma
Interventions
OTHER

Isatuximab

Brand name for interventional drug is Sarclisa

Trial Locations (7)

T6G1Z2

Cross Cancer Institute, Edmonton

B3H1V7

Nova Scotia Health - QEII Health Sciences Centre, Halifax

L8L2X2

Hamilton Health Sciences Centre, Hamilton

K1H8L6

The Ottawa Hospital General Campus, Ottawa

M5G2C1

Princess Margaret Cancer Centre, Toronto

S4T7T1

Allan Blair Cancer Centre, Regina

S7N4H4

Saskatoon Cancer Center, Saskatoon

Sponsors
All Listed Sponsors
lead

Canadian Myeloma Research Group

OTHER

NCT04786028 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | Biotech Hunter | Biotech Hunter